Shionogi & Co., Ltd. (SGIOF)
SGIOF Stock Price Chart
Explore Shionogi & Co., Ltd. interactive price chart. Choose custom timeframes to analyze SGIOF price movements and trends.
SGIOF Company Profile
Discover essential business fundamentals and corporate details for Shionogi & Co., Ltd. (SGIOF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Feb 2018
Employees
4.96K
Website
https://www.shionogi.comCEO
Isao Teshirogi
Description
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
SGIOF Financial Timeline
Browse a chronological timeline of Shionogi & Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 29 Jan 2026
Upcoming earnings on 27 Oct 2025
Revenue estimate is $113.06B.
Earnings released on 28 Jul 2025
EPS came in at $0.32 surpassing the estimated $0.28 by +12.87%, while revenue for the quarter reached $692.38M , missing expectations by -4.73%.
Earnings released on 12 May 2025
EPS came in at $0.30 falling short of the estimated $0.32 by -7.49%, while revenue for the quarter reached $697.72M , missing expectations by -16.01%.
Dividend declared on 12 May 2025
A dividend of $0.22 per share was announced, adjusted to $0.22.
Dividend declared on 12 May 2025
A dividend of $0.22 per share was announced, adjusted to $0.22. The dividend will be paid on 1 Dec 2025.
Earnings released on 29 Jan 2025
EPS came in at $0.38 surpassing the estimated $0.29 by +30.73%, while revenue for the quarter reached $760.85M , missing expectations by -5.14%.
Earnings released on 28 Oct 2024
EPS came in at $0.47 surpassing the estimated $0.33 by +45.63%, while revenue for the quarter reached $809.68M , beating expectations by +0.55%.
Stock split effective on 27 Sept 2024
Shares were split 3 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Jul 2024
EPS came in at $0.74 falling short of the estimated $0.84 by -11.83%, while revenue for the quarter reached $607.57M , beating expectations by +0.12%.
Earnings released on 13 May 2024
EPS came in at $0.78 surpassing the estimated $0.64 by +21.43%, while revenue for the quarter reached $647.74M , missing expectations by -0.98%.
Dividend declared on 13 May 2024
A dividend of $0.22 per share was announced, adjusted to $0.22. The dividend was paid on 19 Jun 2025.
Dividend declared on 13 May 2024
A dividend of $0.59 per share was announced, adjusted to $0.59. The dividend was paid on 2 Dec 2024.
Earnings released on 31 Jan 2024
EPS came in at $0.86 surpassing the estimated $0.46 by +88.88%, while revenue for the quarter reached $759.71M , missing expectations by -6.93%.
Earnings released on 31 Oct 2023
EPS came in at $1.09 surpassing the estimated $0.50 by +118.66%, while revenue for the quarter reached $811.23M , beating expectations by +54.99%.
Earnings released on 31 Jul 2023
EPS came in at $1.01 surpassing the estimated $0.81 by +25.00%, while revenue for the quarter reached $756.38M , beating expectations by +14.28%.
Dividend declared on 10 May 2023
A dividend of $0.56 per share was announced, adjusted to $0.19. The dividend was paid on 21 Jun 2024.
Dividend declared on 10 May 2023
A dividend of $0.50 per share was announced, adjusted to $0.17. The dividend was paid on 1 Dec 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.70 surpassing the estimated $0.19 by +258.68%, while revenue for the quarter reached $666.68M , missing expectations by -3.89%.
Earnings released on 30 Jan 2023
EPS came in at $2.62 surpassing the estimated $2.07 by +26.57%, while revenue for the quarter reached $1.45B , beating expectations by +9.40%.
Earnings released on 31 Oct 2022
EPS came in at $0.51 surpassing the estimated $0.49 by +2.69%, while revenue for the quarter reached $545.94M , missing expectations by -13.15%.
Earnings released on 1 Aug 2022
EPS came in at $0.86 surpassing the estimated $0.57 by +51.85%, while revenue for the quarter reached $528.53M , missing expectations by -0.28%.
Earnings released on 11 May 2022
EPS came in at $1.11 matching the estimated $1.11, while revenue for the quarter reached $944.66M , beating expectations by +14.55%.
Dividend declared on 11 May 2022
A dividend of $0.57 per share was announced, adjusted to $0.19. The dividend was paid on 22 Jun 2023.
Dividend declared on 11 May 2022
A dividend of $0.42 per share was announced, adjusted to $0.14. The dividend was paid on 1 Dec 2022.
Earnings released on 31 Jan 2022
EPS came in at $0.52 falling short of the estimated $0.67 by -23.44%, while revenue for the quarter reached $648.07M , missing expectations by -1.22%.
Earnings released on 1 Nov 2021
EPS came in at $0.61 falling short of the estimated $0.61 by -0.65%, while revenue for the quarter reached $683.37M , beating expectations by +5.13%.
Earnings released on 2 Aug 2021
EPS came in at $0.97 surpassing the estimated $0.53 by +82.74%, while revenue for the quarter reached $620.52M .
Earnings released on 10 May 2021
EPS came in at $0.78 falling short of the estimated $0.94 by -16.68%, while revenue for the quarter reached $658.23M .
Dividend declared on 10 May 2021
A dividend of $0.49 per share was announced, adjusted to $0.16. The dividend was paid on 24 Jun 2022.
Dividend declared on 10 May 2021
A dividend of $0.49 per share was announced, adjusted to $0.16. The dividend was paid on 1 Dec 2021.
Earnings released on 1 Feb 2021
EPS came in at $1.14 surpassing the estimated $0.70 by +62.16%, while revenue for the quarter reached $735.16M .
Earnings released on 30 Oct 2020
EPS came in at $0.86 , while revenue for the quarter reached $729.92M .
Dividend declared on 11 May 2020
A dividend of $0.50 per share was announced, adjusted to $0.17. The dividend was paid on 23 Jun 2021.
Dividend declared on 11 May 2020
A dividend of $0.50 per share was announced, adjusted to $0.17. The dividend was paid on 1 Dec 2020.
SGIOF Stock Performance
Access detailed SGIOF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.